Details
Stereochemistry | RACEMIC |
Molecular Formula | C4H6N4O3 |
Molecular Weight | 158.1154 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)NC1NC(=O)NC1=O
InChI
InChIKey=POJWUDADGALRAB-UHFFFAOYSA-N
InChI=1S/C4H6N4O3/c5-3(10)6-1-2(9)8-4(11)7-1/h1H,(H3,5,6,10)(H2,7,8,9,11)
Molecular Formula | C4H6N4O3 |
Molecular Weight | 158.1154 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdfCurator's Comment: description was created based on several sources, including:
http://tri-k.com/acloxa
Sources: http://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdf
Curator's Comment: description was created based on several sources, including:
http://tri-k.com/acloxa
The aluminum salt of Allantoin, Alcloxa combines the astringent and anti-microbial properties of aluminum with the anti-irritant, soothing and healing properties of Allantoin. Alcloxa is particularly suited for use in anti-perspirants, acne treatments and foot care products. Alcloxa is a compound that combine the properties of aluminum salts with the properties of allantion. The allantion component ehhances the action of the aluminum salts and serves to overcome irritations experienced by many individuals who may be sensitive to the use of aluminum alts. The aluminum component reduces sweat by causing the sweat gland ducts swell. Alcloxa also add to the antiperspirant properties the deodorant effect because of its bacteriostatic action. It showed bacteriostatic properties at concentrations of 0.2% particularly against Gram + bectaria (B. subtilis, S. aureus, P. vulgaris, Pityrosporum ovale). This is ascribable to two different mechanisms: first bacterial growth is retarded due to a decrease in the amount of water present, second aluminum salt have itself an antimicrobial action. In baby products is indicated for its healing reparative action, in the treatment of diaper rash. Also is approved in haemorrhoidal product for its soothing and keratolytic action. In oral care products Alcloxa is useful for its astringent antibacterial properties. It is very indicated in formulations for sensitive teeth, periodontal and gum diseases (like gingivitis, irritable and bleeding gums). Use levels: 0.1-1%. − In antiacne products the slightly astringent effect promotes healing of pustules and acne lesions. It reduces the extension of infected skin eruptions, healing them and developing a soothing action. May be used alone or also in combinations with other antimicrobial agents in order to fight acne more effectively. Use levels: 0.5-2.0%.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | BODYGLIDE FOR HER Approved Usehelps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns. Launch Date1.25902075E12 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
|||
Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
|||
Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
[Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity]. | 1962 Jul-Aug |
|
[The effect of aldioxa on the formation of gastritis induced with sodium hydroxide]. | 1990 Nov |
|
Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia. | 2015 Dec 1 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 00:01:15 UTC 2023
by
admin
on
Thu Jul 06 00:01:15 UTC 2023
|
Record UNII |
344S277G0Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29700
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
||
|
CFR |
21 CFR 347.10
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
||
|
FDA ORPHAN DRUG |
151001
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
||
|
DSLD |
3892 (Number of products:4)
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
||
|
CFR |
21 CFR 310.534
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/13/1232
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
||
|
NCI_THESAURUS |
C29708
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
||
|
EPA PESTICIDE CODE |
85701
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11100
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
4268
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
C74277
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
7490
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
ALLANTOIN
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
1012939
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
DTXSID3020043
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
202-592-8
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
344S277G0Z
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
SUB12779MIG
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
CHEMBL593429
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
204
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
97-59-6
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
M1520
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | Merck Index | ||
|
7606
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
D000481
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
344S277G0Z
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
100000078014
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
15676
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | |||
|
508
Created by
admin on Thu Jul 06 00:01:15 UTC 2023 , Edited by admin on Thu Jul 06 00:01:15 UTC 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE | |||
|
PARENT -> METABOLITE |
|
||
|
PARENT -> METABOLITE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |